5 completed, 2 active not recruiting, 1 terminated. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Active not recruiting 2, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow anagrelide: new trials by email Literature Review of anagrelide trials Research Report on anagrelide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) Bomedemstat, Anagrelide, Busulfan - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 340 | 2023-12-31 | 2026-10-02 |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance Ropeginterferon alfa-2b, Anagrelide - Essential Thrombocythemia | Phase 3 | Active not recruiting | PharmaEssentia | 174 | 2020-08-25 | 2026-07-22 |
| The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Anagrelide, Ruxolitinib (JAKAVI®), IFNα/ PegIFNα - Essential Thrombocythemia | Phase 2 / Phase 3 | Terminated | French Innovative Leukemia Organisation | 13 | 2017-01-03 | 2021-06-29 |
| Anagrelide Retard in Essential Thrombocythemia Anagrelide retard, Thromboreductin - Essential Thrombocythemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 106 | 2014-02-01 | 2015-07-29 |
| Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) ruxolitinib tablets, Best Available Therapy (BAT) - Polycythemia Vera | Phase 3 | Completed | Incyte Corporation | 222 | 2010-10-27 | 2019-03-06 |
| Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia SPD422 (anagrelide hydrochloride) - Essential Thrombocythemia (ET) | Phase 3 | Completed | Shire | 41 | 2010-10-27 | 2021-06-09 |
| Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Anagrelide Hydrochloride - Essential Thrombocythemia (ET) | Phase 3 | Completed | Shire | 53 | 2010-10-27 | 2021-06-09 |
| Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Anagrelide, Hydroxyurea - Essential Thrombocythaemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 2002-09-01 | 2010-10-06 |
Thrombocythemia, Essential (7) · Myeloproliferative Disorders (2) · Polycythemia Vera (1)
AOP Orphan Pharmaceuticals AG (2) · Shire (2) · French Innovative Leukemia Organisation (1) · Incyte Corporation (1) · Merck Sharp & Dohme LLC (1) · PharmaEssentia (1)
Japan (5) · France (4) · Canada (3) · China (3) · Germany (3) · Hungary (3) · Italy (3) · Poland (3) · South Korea (3) · United States (3) · Argentina (2) · Australia (2) · Austria (2) · Belgium (2) · Hong Kong (2)
Craig Zimmerman, PhD (1) · Heinz Gisslinger, Prof., MD (1) · Mark Jones, MD (1) · Srdan Verstovsek, MD,PhD (1) · Toshiaki Sato, MD/PhD (1)
PMID 23315161, PMID 25160063, PMID 25629741, PMID 27102499, PMID 28193568, PMID 29396713, PMID 30121892, PMID 31982039, PMID 35924546, PMID 41193116, PMID 41890273
2023 (1)